Thursday, October 28, 2004

From Health Canada:
New Safety Information Regarding PERMAX and Occurrence of Cardiac Valvulopathy / Fibrosis.
Dear HealthCare Professional:

Shire BioChem Inc., following discussions with Health Canada, is alerting you to important new WARNINGS concerning the risk of cardiac valvulopathy associated with use of PERMAX (pergolide mesylate). The Product Monograph for PERMAX is being revised to reflect the following additions...

No comments: